Anti mouse nkp46 apc

Manufactured by BioLegend

Anti-mouse NKp46 APC is a flow cytometry reagent that binds to the NKp46 receptor expressed on mouse natural killer (NK) cells. NKp46 is a key activating receptor involved in the recognition and killing of target cells by NK cells. The APC (Allophycocyanin) fluorescent dye is conjugated to the anti-NKp46 antibody, enabling detection of NKp46-expressing cells by flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Pe cyanine7, by Thermo Fisher Scientific (2 mentions) Evolve 605 clone 30 f11, by Thermo Fisher Scientific (2 mentions) Pe anti mouse cd3 molecular complex 17a2, by BD (2 mentions) Apc cy7 anti mouse human cd11b clone m1 70, by BioLegend (2 mentions) Anti cd27 monoclonal antibody lg 7f9 fitc, by Thermo Fisher Scientific (2 mentions)

Spelling variants of this product

Anti-NKp46 (16 citations) NKp46-APC (3 citations)

2 protocols using anti mouse nkp46 apc

Comprehensive NK Cell Immunophenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

The NK cell flow cytometry panel included the following directly conjugated primary antibodies: anti-mouse CD45, eBioscience eVolve 605 clone: 30-F11 (Ref # 83-0451-42, Invitrogen), PE anti-mouse CD3 molecular complex (17A2) (mat. #: 555275, BD biosciences), anti-mouse NKp46 APC (Ref # 17-3351-82), APC/Cy7 anti-mouse/human CD11b clone: M1/70 (cat# 101226, BioLegend), anti-Cd27 Monoclonal Antibody (LG.7F9) FITC (eBioscience™, Thermo Scientific, cat # 11-0271-82), and (Klrg1 Monoclonal Antibody (2F1) PE-Cyanine7 (eBioscience, Thermo Scientific, cat # 25-5893-82). Gating strategies are as follows:
NK cell: live/CD45/CD3-/NK1.1+
Mature NK cell: live/CD45/CD3-/NK1.1+/KRLG1+
Activated NK cell: live/CD45/CD3-/NK1.1+/CD11b+
NK cell subset 1: live/CD45/CD3-/NK1.1+/CD11b-CD27-
NK cell subset 2: live/CD45/CD3-/NK1.1+/CD11b-CD27+
NK cell subset 3: live/CD45/CD3-/NK1.1+/CD11b+CD27+
NK cell subset 4: live/CD45/CD3-/NK1.1+/CD11b+CD27-

Huntington K.E., Louie A.D., Srinivasan P.R., Schorl C., Lu S., Silverberg D., Newhouse D., Wu Z., Zhou L., Borden B.A., Giles F.J., Dooner M., Carneiro B.A, & El-Deiry W.S. (2023). GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. International Journal of Molecular Sciences, 24(13), 10870.

+ Open protocol

+ Expand

Comprehensive NK Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

The NK cell flow cytometry panel included the following directly-conjugated primary antibodies: Anti-mouse CD45, eBioscience eVolve 605 clone: 30-F11 (Ref # 83-0451-42, Invitrogen), PE anti-mouse CD3 molecular complex (17A2) (mat. #: 555275, BD biosciences), Anti-mouse NKp46 APC (Ref # 17-3351-82), APC/Cy7 anti-mouse/human CD11b clone: M1/70 (cat# 101226, BioLegend), anti-Cd27 Monoclonal Antibody (LG.7F9) FITC (eBioscience™, Thermo Scientific, cat # 11-0271-82), and (Klrg1 Monoclonal Antibody (2F1) PE-Cyanine7 (eBioscience, Thermo Scientific, cat # 25-5893-82). Gating strategies are as follows:
NK cell: live/CD45/CD3−/NK1.1+
Mature NK cell: live/CD45/CD3−/NK1.1+/ KRLG1+
Activated NK cell: live/CD45/CD3−/NK1.1+/CD11b+
NK cell subset 1: live/CD45/CD3−/NK1.1+/ CD11b−CD27−
NK cell subset 2: live/CD45/CD3−/NK1.1+/ CD11b−CD27+
NK cell subset 3: live/CD45/CD3−/NK1.1+/ CD11b+CD27+
NK cell subset 4: live/CD45/CD3−/NK1.1+/ CD11b+CD27−

Huntington K.E., Louie A.D., Srinivasan P.R., Schorl C., Lu S., Silverberg D., Newhouse D., Wu Z., Zhou L., Borden B.A., Giles F.J., Dooner M., Carneiro B.A, & El-Deiry W.S. (2023). GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. bioRxiv.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!